Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (20071)	5/18/2006 2:07:02 PM
From: former_pgs	Read Replies (3) of 52153

>Why is that?< My interpretation is driven by my assumption that this recently announced analysis is due to events that occurred subsequent to the review announced on april 27. If this assumption is correct, then the only new news the DMB would be receiving in the interim would be bad news (deaths / toxicity). Not to state the obvious (or be flip), but centers don't call into the DMB and say "Patient X is really living a lot longer than we thought"... Big flaw in this is my assumption that this upcoming analysis is completely unrelated to the previously announced analysis. The alternate explanation is that the interim analysis was very favorable, and the DMB was deliberating over the last 3 weeks regarding the feasibility / issues surrounding early termination of the trial (as has been discussed here before).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next